## 3 PDT in Veterinary Oncology
### Melanomas
\begin{table}
\begin{tabular}{l l l l l l} \hline \hline
**Ref.** & **Neoplasm** & **Patients** & **PDT Protocol** & **Main Results** \\ \hline \multirow{4}{*}{[121]} & \multirow{4}{*}{Hemangiopericytoma} & \multirow{4}{*}{16 Dogs} & **PS:**HPPH, 0.3 mg/kg, iv & \(\bullet\) & Recurrence occurred in 56\% of dogs (2 to 29 months after treatment) \\  & & & **Light:** Argon laser dye, 100 J/cm\({}^{2}\), & \(\bullet\) & Results are comparable or inferior to other forms of treatment \\ \hline \multirow{4}{*}{[109]} & \multirow{4}{*}{Chondrosarcoma} & \multirow{4}{*}{1 Dog} & **PS:**HPPH, 0.3 mg/kg, iv & \(\bullet\) & No relevant side effects were observed \\  & & & **Light:** Potassium titanyl & \(\bullet\) & PDT showed a limited capacity to \\  & & & 100 J/cm\({}^{2}\), 665 nm, 2 sessions & \(\bullet\) & control intranasal malignancies \\ \hline \multirow{4}{*}{[83]} & \multirow{4}{*}{Fibrosarcoma} & \multirow{4}{*}{3 Dogs} & **PS:**CASPc, 1 mg/kg, iv & \(\bullet\) & 33\% no response \\  & & & **PS:**CASPc, 1 mg/kg, iv & \(\bullet\) & 33\% recurrence after nine months \\  & & & **Light:** Argon laser, 50–150 J/cm\({}^{2}\), & \(\bullet\) & 33\% entered remission, but regional \\  & & & 675 nm, 1 session & \(\bullet\) & metastasis occurred after 15 months \\  & & & & & and in the original site after \\  & & & & & 18 months \\ \hline \multirow{4}{*}{[83]} & \multirow{4}{*}{Hemangiopericytoma} & \multirow{4}{*}{4 Dogs} & **PS:**CASPc, 1 mg/kg, iv & \(\bullet\) & \(\bullet\) \\  & & & **Light:** Argon laser, 50–150 J/cm\({}^{2}\), & \(\bullet\) & Remission in all dog evaluation \\  & & & 675 nm, 1 session & \(\bullet\) & times from 9 to 21 months) \\ \hline \multirow{4}{*}{[113]} & \multirow{4}{*}{Sarcoma} & \multirow{4}{*}{1 Dog} & **PS:**CASPc, 1 mg/kg, iv & \(\bullet\) & Died or killed because of metastatic \\  & & & **Light:** Argon laser, 100 J/cm\({}^{2}\), 675 nm, & \(\bullet\) & No evidence of tumor at necropsy \\  & & & & & \\ \hline \multirow{4}{*}{[84]} & \multirow{4}{*}{Histiocytoma} & \multirow{4}{*}{1 Dog} & **PS:**ZnPcS\({}_{4}\), 0.5 mg/kg, iv & \(\bullet\) & Partial response \\  & & & **Light:** Diode laser, 100 J/cm\({}^{2}\), & \(\bullet\) & Partial response \\  & & & 675 \(\pm\) 0.2 nm, 1 session & \(\bullet\) & Partial response \\ \hline \multirow{4}{*}{[84]} & \multirow{4}{*}{Spindle cell Sarcoma} & \multirow{4}{*}{1 Dog} & **PS:**ZnPcS\({}_{4}\), 4.0 mg/kg, iv & \(\bullet\) & \(\bullet\) \\  & & & **Light:** Diode laser, 100 J/cm\({}^{2}\), & \(\bullet\) & Complete response \\  & & & 675 \(\pm\) 0.2 nm, 1 session & \(\bullet\) & 88\% complete remission \\  & & & **PS:**AICIPc-nano, 13.3 \(\mu\)M, & \(\bullet\) & Necrosis and hemorrhage were \\  & & & intra/peritumoral & & observed in the histological \\  & & & **Light:** LED, 120 J/cm\({}^{2}\), 658–662 nm, & \(\bullet\) & evaluation, but without cancer cells \\  & & & 1–4 sessions & \(\bullet\) & (except for one case) \\  & & & & & \\  & & & & & \\  & & & & & \\ \hline \multirow{4}{*}{[122]} & \multirow{4}{*}{Malignant soft tissue} & \multirow{4}{*}{10 Dog} & **PS:** ICG, 5 mg/9 mL, tumor bed & \(\bullet\) & The overall canine survival time \\  & & & **Light:** Broadband light, 48 J/cm\({}^{2}\), & \(\bullet\) & ranged from 225 to 1.901 days \\  & & & 60–800 nm, 3–21 sessions & \(\bullet\) & (median survival time: 767 days) \\ \hline \multirow{4}{*}{[122]} & \multirow{4}{*}{Malignant soft tissue sarcoma} & \multirow{4}{*}{6 Cats} & **PS:** ICG, 5 mg/9 mL, tumor bed & \(\bullet\) & The overall feline survival time \\  & & & **Light:** Broadband light, 48 J/cm\({}^{2}\), & \(\bullet\) & ranged from 383 to 1.521 days \\  & & & 60–800 nm, 3–21 sessions & \(\bullet\) & (median survival time: 1.344 days) \\ \hline \multirow{4}{*}{[123]} & \multirow{4}{*}{Injection-site sarcoma} & \multirow{4}{*}{37 Cats} & **PS:** AO, 1 \(\mu\)g/mL & \(\bullet\) & No recurrence cases were observed \\  & & & **PS:** AO, 1 \(\mu\)g/mL & \(\bullet\) & in PDS-PDT-treated cats \\  & & & **Light:** Surgical light, 24 V/250 Watt, & \(\bullet\) & Animals submitted to the PDS-PDT \\  & & & 80,000 Lux, 1 session & \(\bullet\) & modality presented a higher \\  & & & & & disease-free survival rate \\ \hline \hline \end{tabular}
\end{table}